Long‐term complete remission and peripheral biomarkers in Hodgkin lymphoma patients after decitabine‐plus‐camrelizumab epi‐immunotherapy and treatment cessation

Patients with relapsed/refractory classical Hodgkin lymphoma (cHL) achieve complete response (CR) after decitabine‐plus‐camrelizumab therapy, while long‐term outcome especially after treatment discontinuation remains unclear. We present a retrospective analysis of 87 relapsed/refractory cHL patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chunmeng, Pan, Yuting, Liu, Yang, Guo, Bing, Shi, Jinhong, Rong, Guanghua, Guo, Zhipeng, Li, Zhifang, Yang, Qingming, Nie, Jing, Han, Weidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665599/
https://www.ncbi.nlm.nih.gov/pubmed/38020717
http://dx.doi.org/10.1002/mco2.428

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10665599/
https://www.ncbi.nlm.nih.gov/pubmed/38020717
http://dx.doi.org/10.1002/mco2.428

Ejemplares similares